Finding an optimal solution for breast cancer treatment drug Tamoxifen

German scientists say they have found a way to increase the effectiveness of the drug Tamoxifen in breast cancer patients who do not respond well to this treatment.

Tamoxifen works by blocking the hormone estrogen from binding to cancer cells, but it needs to be converted by the enzyme CYP2D6 into its active form, (Z)-endoxifen. About a third of breast cancer patients have genetically low levels of this enzyme, making the drug less effective.

According to a study published in the journal Clinical Cancer Research, supplementing (Z)-endoxifen to these patients helped achieve blood drug concentrations equivalent to those of normal metabolizers without increasing side effects.

This is the “first effective solution” to the long-standing problem of Tamoxifen – its ineffectiveness in a significant proportion of breast cancer patients, said lead researcher Dr. Matthias Schwab of the Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology in Stuttgart.

A similar trial sponsored by Atossa Therapeutics is currently underway in the US in premenopausal women. Atossa Therapeutics plans to apply for US Food and Drug Administration (FDA) approval in 2026.

VNA

Source: https://nhandan.vn/tim-ra-giai-phap-toi-uu-hoa-thuoc-dieu-tri-ung-thu-vu-tamoxifen-post916221.html